(Q34189713)

31 July 2017

1 reference

title

Hepatitis C in clinical practice (English)

1 reference

31 July 2017

Larson AM

1

1 reference

31 July 2017

Carithers RL

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

Journal of Internal Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

249

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

111-120

1 reference

Epidemiology of hepatitis C: geographic differences and temporal trends

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Diagnostic testing for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Therapy of hepatitis C: re-treatment with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Relationship between the presence of circulating anti-GOR and hepatitis C viremia/genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Mother-to-infant transmission of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Diagnostic tests for hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Epidemiological and clinical features of Budd-Chiari syndrome in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2001.00781.X

10.1046/J.1365-2796.2001.00781.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference